Australian biotech Neurizon Therapeutics (ASX: NUZ) is setting out to redefine how neurodegenerative diseases are treated, ...
The USA has completed its withdrawal from the World Health Organization (WHO), according to a joint announcement by the US ...
In a new report, DelveInsight argues the gastroesophageal reflux disease market remains constrained by limited approved ...
Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and ...
The Russian government has extended the permit for domestic pharmaceutical companies Promomed and PSK Pharma to produce ...
Japanese pharma Daiichi Sankyo (TSE: 4568) and British partner AstraZeneca (LSE: AZN) said Enhertu (trastuzumab deruxtecan) ...
US biopharma Corcept Therapeutics (Nasdaq: CORT) says its Phase III ROSELLA trial met its overall survival primary endpoint ...
Japanese drugmaker Daiichi Sankyo has appointed Veronika Rozehnal to succeed Jürgen Müller as the Head of the Translational ...
Janux Therapeutics’ shares closed up 14% at $15.14, after it announced a collaboration and exclusive worldwide license ...
January 23, 2026 Following the positive COAST 1 results in September 2025, two additional global Phase III studies – SHORE and COAST 2 of amlitelimab, a fully human non-T cell depleting monoclonal ...
USA-based Medicus Pharma’ Antev subsidiary has agreed to amend its licensing deal with UK-based medical research organization LifeArc relating to teverelix, an investigational next generation ...
Privately-held UK drug developer Ellipses Pharma has entered into a collaboration and licence agreement with China-based Innolake Biopharm to develop a clinical stage first-in-class antibody drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback